参考文献/References:
[1]郭秀臣,全丽娜,李红,等.多发性骨髓瘤患者骨髓中Treg 细
胞与预后相关性研究[J].实用肿瘤学杂志,2014,28(1):54-58.
[2]赵霞,许庆,丁慧芳,等.DC-CIK 联合化疗对多发性骨髓瘤
患者细胞免疫功能的影响[J].中国免疫学杂志,2015,31(4):490-
496.
[3]张之南,沈悌.血液病诊断及疗效标准[M].第3 版.北京:科学
出版社,2007:232-233.
[4]龚非力.医学免疫学[M].北京:人民卫生出版社,2008.
[5]Shen CJ,Yuan ZH,Liu YX,et al.Increased numbers of T
helper 17 cells and the correlation with clinicopathological char-
acteristics in multiple myeloma [J].J Int Med Res,2012,40 (2):
556-564.
[6]黄亚丽,杨丽萍,廖建军,等.T 细胞亚群与NK 细胞在难治
性多发性骨髓瘤患者表达水平的研究[J].黑龙江医药,2015,28
(3):485-488
相似文献/References:
[1]黄珍艳.实验室指标对多发性骨髓瘤的诊断价值分析[J].医学信息,2018,31(05):155.[doi:10.3969/j.issn.1006-1959.2018.05.056]
HUANG Zhen-yan.Diagnostic Value of Laboratory Markers for Multiple Myeloma[J].Journal of Medical Information,2018,31(01):155.[doi:10.3969/j.issn.1006-1959.2018.05.056]
[2]冯江芳.多发性骨髓瘤患者校正血钙的临床分析[J].医学信息,2018,31(10):87.[doi:10.3969/j.issn.1006-1959.2018.10.026]
FENG Jiang-fang.Clinical Analysis of Corrected Serum Calcium in Patients with Multiple Myeloma[J].Journal of Medical Information,2018,31(01):87.[doi:10.3969/j.issn.1006-1959.2018.10.026]
[3]甘红婉,肖德俊,曾 瑜,等.奥洛他定联合匹多莫德治疗慢性荨麻疹的疗效及对外周血淋巴细胞亚群影响[J].医学信息,2018,31(21):144.[doi:10.3969/j.issn.1006-1959.2018.21.041]
GAN Hong-wan,XIAO De-jun,ZENG Yu,et al.Efficacy of Olopatadine Combined with Pidotimod in the Treatment of Chronic Urticaria and Its Effect on Peripheral Blood Lymphocyte Subsets[J].Journal of Medical Information,2018,31(01):144.[doi:10.3969/j.issn.1006-1959.2018.21.041]
[4]王晓雪,王芝涛,秦 慧.血小板与淋巴细胞比值在多发性骨髓瘤预后中的价值[J].医学信息,2022,35(12):109.[doi:10.3969/j.issn.1006-1959.2022.12.026]
WANG Xiao-xue,WANG Zhi-tao,QIN Hui.Prognostic Value of Platelet to Lymphocyte Ratio in Multiple Myeloma[J].Journal of Medical Information,2022,35(01):109.[doi:10.3969/j.issn.1006-1959.2022.12.026]
[5]王 然,孙言非.血清免疫固定电泳、血清蛋白电泳及免疫球蛋白定量对
多发性骨髓瘤的临床诊断价值[J].医学信息,2019,32(11):173.[doi:10.3969/j.issn.1006-1959.2019.11.054]
WANG Ran,SUN Yan-fei.Clinical Diagnostic Value of Serum Immunofixation Electrophoresis,Serum Protein Electrophoresis and Immunoglobulin Quantification for Multiple Myeloma[J].Journal of Medical Information,2019,32(01):173.[doi:10.3969/j.issn.1006-1959.2019.11.054]
[6]金 英.硼替佐米治疗老年多发性骨髓瘤的效果[J].医学信息,2020,33(06):146.[doi:10.3969/j.issn.1006-1959.2020.06.047]
JIN Ying.Effect of Bortezomib in the Treatment of Elderly Multiple Myeloma[J].Journal of Medical Information,2020,33(01):146.[doi:10.3969/j.issn.1006-1959.2020.06.047]
[7]燕法红,邱志远,李乾鹏,等.激活蛋白-1家族JunB、c-Jun、c-Maf、c-Fos在多发性骨髓瘤中的表达[J].医学信息,2021,34(23):44.[doi:10.3969/j.issn.1006-1959.2021.23.012]
YAN Fa-hong,QIU Zhi-yuan,LI Qian-peng,et al.Expression of Activator Protein-1 Family JunB,c-Jun,c-Maf,c-Fos in Multiple Myeloma[J].Journal of Medical Information,2021,34(01):44.[doi:10.3969/j.issn.1006-1959.2021.23.012]
[8]刘文玲,朱明明,马德花.miR-125b在多发性骨髓瘤中的表达及与预后的关系[J].医学信息,2023,36(21):61.[doi:10.3969/j.issn.1006-1959.2023.21.013]
LIU Wen-ling,ZHU Ming-ming,MA De-hua.Expression of miR-125b in Multiple Myeloma and its Relationship with Prognosis[J].Journal of Medical Information,2023,36(01):61.[doi:10.3969/j.issn.1006-1959.2023.21.013]
[9]张少晗,应燕萍,赵慧函,等.1990-2019年我国多发性骨髓瘤疾病负担及其变化趋势分析[J].医学信息,2022,35(22):23.[doi:10.3969/j.issn.1006-1959.2022.22.004]
ZHANG Shao-han,YING Yan-ping,ZHAO Hui-han,et al.Analysis of the Burden of Multiple Myeloma and its Changing Trend in China from 1990 to 2019[J].Journal of Medical Information,2022,35(01):23.[doi:10.3969/j.issn.1006-1959.2022.22.004]
[10]覃泽东,夏玉梅,陈 莉,等.多发性骨髓瘤合并颅内浆细胞瘤的临床及影像学特点分析[J].医学信息,2021,34(05):111.[doi:10.3969/j.issn.1006-1959.2021.05.031]
QIN Ze-dong,XIA Yu-mei,CHEN Li,et al.Analysis of Clinical and Imaging Characteristics of Multiple Myeloma Combined with Intracranial Plasmacytoma[J].Journal of Medical Information,2021,34(01):111.[doi:10.3969/j.issn.1006-1959.2021.05.031]